PL3207938T3 - Warianty CTLA-4 - Google Patents

Warianty CTLA-4

Info

Publication number: PL3207938T3
Authority: PL; Poland
Prior art keywords: ctla; variants
Prior art date: 2012-05-11

Application number

PL17163638T

Other languages

English (en)

Inventor

Ralph Minter

Julie DOUTHWAITE

Jacques Moisan

Michael Bowen

Steven RUST

Cyril PRIVESENTZEV

Original Assignee

Medimmune Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-11

Filing date

2013-03-11

Publication date

2020-07-13

2013-03-11 Application filed by Medimmune Limited filed Critical Medimmune Limited

2020-07-13 Publication of PL3207938T3 publication Critical patent/PL3207938T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/425—Zeins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Botany (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17163638T 2012-05-11 2013-03-11 Warianty CTLA-4 PL3207938T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261645686P	2012-05-11	2012-05-11
EP17163638.4A EP3207938B1 (en)	2012-05-11	2013-03-11	Ctla-4 variants
PCT/US2013/030179 WO2013169338A1 (en)	2012-05-11	2013-03-11	Ctla-4 variants
EP13787673.6A EP2863936A4 (en)	2012-05-11	2013-03-11	CTLA-4 VARIANTS

Publications (1)

Publication Number	Publication Date
PL3207938T3 true PL3207938T3 (pl)	2020-07-13

Family

ID=49551120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17163638T PL3207938T3 (pl)	2012-05-11	2013-03-11	Warianty CTLA-4

Country Status (17)

Country	Link
US (2)	US9884902B2 (pl)
EP (2)	EP2863936A4 (pl)
JP (1)	JP6228971B2 (pl)
KR (1)	KR102133060B1 (pl)
CN (2)	CN107540742B (pl)
AU (1)	AU2013260172B2 (pl)
BR (1)	BR112014026718B1 (pl)
CA (1)	CA2868748C (pl)
DK (1)	DK3207938T3 (pl)
ES (1)	ES2777778T3 (pl)
HK (1)	HK1209644A1 (pl)
HU (1)	HUE048925T2 (pl)
MX (1)	MX355234B (pl)
PL (1)	PL3207938T3 (pl)
RU (1)	RU2671465C2 (pl)
SG (2)	SG10201609447XA (pl)
WO (1)	WO2013169338A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102133060B1 (ko) *	2012-05-11	2020-07-10	메디뮨 리미티드	Ｃｔｌａ－４ 변이체
HUE047077T2 (hu) *	2012-06-29	2020-04-28	Bristol Myers Squibb Co	Eljárások glikoprotein aggregáció csökkentésére
WO2014138188A1 (en) *	2013-03-07	2014-09-12	The General Hospital Corporation	Human ctla4 mutants and use thereof
JP2017508446A (ja) *	2014-01-28	2017-03-30	北京韓美薬品有限公司	二機能性融合タンパク質及びその製造方法並びに使用
EP3733696A1 (en)	2015-01-13	2020-11-04	City of Hope	Ctla4-binding protein peptide-linker masks
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR20240046641A (ko)	2015-04-17	2024-04-09	알파인 이뮨 사이언시즈, 인코포레이티드	조율가능한 친화성을 갖는 면역조절 단백질
WO2017034244A1 (ko) *	2015-08-21	2017-03-02	한양대학교 산학협력단	중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
US11351224B2 (en)	2015-08-21	2022-06-07	Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University)	Pharmaceutical composition for preventing and treating transplant rejection
EP3336100B1 (en)	2015-08-21	2021-01-13	IUCF-HYU (Industry-University Cooperation Foundation Hanyang University)	Peptide having effect of preventing or treating central nervous system diseases and pharmaceutical composition for preventing and treating central nervous system diseases, containing same as active ingredient
WO2017048878A1 (en) *	2015-09-14	2017-03-23	Alpine Immune Sciences, Inc.	Tunable variant immunoglobulin superfamily domains and engineered cell therapy
UA125611C2 (uk)	2015-12-14	2022-05-04	Макродженікс, Інк.	Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
KR101918456B1 (ko) *	2015-12-15	2018-11-16	앱클론(주)	Cd80 및 cd86에 특이적으로 결합하는 항체
NZ746934A (en)	2016-04-15	2023-11-24	Alpine Immune Sciences Inc	Cd80 variant immunomodulatory proteins and uses thereof
KR20230051601A (ko)	2016-04-15	2023-04-18	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2018022945A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
EP3596115A1 (en)	2017-03-16	2020-01-22	Alpine Immune Sciences, Inc.	Pd-l2 variant immunomodulatory proteins and uses thereof
SG11201907769XA (en)	2017-03-16	2019-09-27	Alpine Immune Sciences Inc	Cd80 variant immunomodulatory proteins and uses thereof
IL309444A (en)	2017-05-24	2024-02-01	Als Therapy Development Inst	Therapeutic anti-CD40 ligand antibodies
CA3077509A1 (en) *	2017-10-10	2019-04-18	Alpine Immune Sciences, Inc.	Ctla-4 variant immunomodulatory proteins and uses thereof
CN111712515A (zh)	2017-10-18	2020-09-25	高山免疫科学股份有限公司	变体icos配体免疫调节蛋白及相关组合物和方法
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
JP2022505045A (ja) *	2018-11-02	2022-01-14	ベイジンブイディージェイバイオカンパニー，リミテッド	修飾されたｃｔｌａ４およびその使用方法
CN113645990A (zh) *	2019-04-10	2021-11-12	肯塔基大学研究基金会	改良的前列腺凋亡反应-4(par-4)多肽及其生产和使用方法
EP4090736A4 (en) *	2020-01-11	2024-02-21	Yale University	COMPOSITIONS AND METHODS FOR THE TREATMENT, RELIEF AND/OR PREVENTION OF ILLNESSES OR DISORDERS ASSOCIATED WITH DNASE1 AND/OR DNASE1L3 DEFICIENCY
AU2021252514A1 (en) *	2020-04-06	2022-11-10	Lung Biotechnology Pbc	Modular synthetic receptors and methods of use
EP4412747A1 (en) *	2021-10-08	2024-08-14	Kashiv Biosciences, LLC	Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057995A1 (en) *	2021-10-08	2023-04-13	Kashiv Biosciences, Llc	Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) *	2021-12-17	2024-07-25	Kashiv Biosciences, Llc	An improved assay method for determining the potency of recombinant protein
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
WO2024211211A1 (en)	2023-04-03	2024-10-10	Regeneron Pharmaceuticals, Inc.	Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2123001T5 (es)	1991-06-27	2009-04-16	Bristol-Myers Squibb Company	Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0975355A2 (en) *	1996-06-14	2000-02-02	Smithkline Beecham Corporation	Hexameric fusion proteins and uses therefor
AU2001263466C1 (en) *	2000-05-26	2006-10-26	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007007654A1 (ja)	2005-07-07	2007-01-18	Toshiba Lighting & Technology Corporation	放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) *	2006-10-20	2006-11-29	Cambridge Antibody Tech	Protein variants
CN101998965B (zh)	2007-11-01	2014-03-12	安斯泰来制药有限公司	免疫抑制性多肽与核酸
DK2536745T3 (en) *	2010-02-19	2016-08-22	Xencor Inc	NOVEL CTLA4-IG immunoadhesins
WO2011113019A2 (en) *	2010-03-12	2011-09-15	Abbott Biotherapeutics Corp.	Ctla4 proteins and their uses
KR102133060B1 (ko) *	2012-05-11	2020-07-10	메디뮨 리미티드	Ｃｔｌａ－４ 변이체

2013
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active IP Right Grant
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en active Application Filing
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
2015
- 2015-10-28 HK HK15110585.3A patent/HK1209644A1/xx unknown
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2863936A1 (en)	2015-04-29
CA2868748C (en)	2022-07-26
EP2863936A4 (en)	2016-10-05
AU2013260172A1 (en)	2014-10-23
WO2013169338A1 (en)	2013-11-14
EP3207938B1 (en)	2019-12-25
HK1209644A1 (en)	2016-04-08
BR112014026718B1 (pt)	2021-05-18
MX355234B (es)	2018-04-11
AU2013260172B2 (en)	2017-11-23
US20180208639A1 (en)	2018-07-26
JP2015523328A (ja)	2015-08-13
US9884902B2 (en)	2018-02-06
KR20150014443A (ko)	2015-02-06
RU2014150092A (ru)	2016-07-10
CN107540742A (zh)	2018-01-05
BR112014026718A2 (pt)	2017-07-18
CN107540742B (zh)	2021-06-29
US20150104450A1 (en)	2015-04-16
CN104302309B (zh)	2017-07-28
EP3207938A3 (en)	2017-11-01
MX2014013092A (es)	2015-03-03
DK3207938T3 (da)	2020-03-16
ES2777778T3 (es)	2020-08-06
SG10201609447XA (en)	2017-01-27
HUE048925T2 (hu)	2020-09-28
KR102133060B1 (ko)	2020-07-10
SG11201405968SA (en)	2014-11-27
RU2671465C2 (ru)	2018-10-31
JP6228971B2 (ja)	2017-11-08
CN104302309A (zh)	2015-01-21
EP3207938A2 (en)	2017-08-23
CA2868748A1 (en)	2013-11-14

Publication	Publication Date	Title
HK1209644A1 (en)	2016-04-08	Ctla-4 variants ctla-4
GB201304182D0 (en)	2013-04-24	No details
GB201403961D0 (en)	2014-04-23	No details
DK2830816T3 (en)	2020-02-17	Hidtil ukendt coatingkoncept
HK1208025A1 (en)	2016-02-19	Aminoimidazopyridazines
PL2802470T3 (pl)	2018-01-31	Autobus typu kabriolet
GB201411220D0 (en)	2014-08-06	No details
GB201420527D0 (en)	2014-12-31	Electrical-wire-protecting member
HK1204445A1 (en)	2015-11-20	Surrobody cojugates surrobody
GB2518076B (en)	2017-09-06	Electrical-wire-protecting member
SG11201408016XA (en)	2015-03-30	3-o-heteroaryl-ingenol
EP2873363A4 (en)	2016-03-02	DIOPSIMETER
GB201317386D0 (en)	2013-11-13	Unperpants
GB201313844D0 (en)	2013-09-18	No details
GB201502236D0 (en)	2015-03-25	Headshaft
GB201403415D0 (en)	2014-04-16	No details
GB2505920B (en)	2016-07-06	Maxi-bib
GB201322955D0 (en)	2014-02-12	No details
GB201400108D0 (en)	2014-02-19	No details
GB201302155D0 (en)	2013-03-27	No details
GB201300109D0 (en)	2013-02-20	No details
GB201310646D0 (en)	2013-07-31	No details
GB201220388D0 (en)	2012-12-26	Vertergo
AU345893S (en)	2012-12-04	Treehouse
GB201219536D0 (en)	2012-12-12	Jurasic